Target intelligence / Profile preview

Proinsulin-specific CD4 T-cell receptor (Proinsulin-specific CD4 TCR)

Target
Proinsulin-specific CD4 TCR
Molecular classification
Receptor, Other
01

Overview

The proinsulin-specific CD4 T-cell receptor (TCR) is a key immunological molecule expressed on the surface of CD4+ T helper cells that plays a central role in the pathogenesis of Type 1 Diabetes (T1D). These TCRs specifically recognize proinsulin-derived peptides (such as the C-peptide or insulin A and B chains) presented by human leukocyte antigen (HLA) class II molecules (predominantly high-risk alleles like HLA-DR4, HLA-DQ8, and HLA-DQ2) on antigen-presenting cells. In individuals with T1D, the engagement of these TCRs by proinsulin epitopes triggers the activation and clonal expansion of autoreactive CD4+ effector T cells, which orchestrate the autoimmune destruction of insulin-producing pancreatic beta cells. Consequently, the proinsulin-specific CD4 TCR is a highly attractive therapeutic target for antigen-specific immunotherapies aimed at halting or reversing T1D progression without causing systemic immunosuppression.\n\nTherapeutic strategies targeting this receptor include peptide immunotherapies (such as proinsulin C19-A3 and IMCY-0098) designed to induce immune tolerance, anergy, or regulatory T cell (Treg) expansion. Additionally, novel biologics like Cue Biopharma's CUE-301 utilize an Immuno-STAT platform to deliver a proinsulin peptide-MHC complex alongside PD-L1, selectively binding to the proinsulin-specific CD4 TCR to deliver an inhibitory signal and dampen autoreactive T-cell responses. Other approaches involve adoptive cell therapy using regulatory T cells engineered with recombinant proinsulin-specific CD4 TCRs to restore immune homeostasis in the pancreas. Clinical monitoring of these therapies typically relies on biomarkers such as stimulated C-peptide levels to assess beta-cell preservation, and the frequency of proinsulin-specific T cells via tetramer or ELISpot assays.

Other names
Proinsulin-specific CD4 TCRProinsulin-specific T-cell receptorPreproinsulin-specific CD4 T-cell receptorPreproinsulin-specific CD4 TCRInsulin-specific CD4 T-cell receptor
02

Mechanism of action

Selective inhibition of autoreactive CD4+ T cells via TCR-targeted delivery of inhibitory signals (such as PD-L1); induction of antigen-specific immune tolerance or anergy through peptide-MHC presentation; generation of antigen-specific cytolytic CD4+ T cells to eliminate antigen-presenting cells; and adoptive transfer of regulatory T cells engineered with proinsulin-specific TCRs to suppress pathogenic effector T cells.

03

Biological functions

Immune responseSignal transductionOther
04

Disease associations

OtherInflammation
05

Safety considerations

Risk of systemic hypersensitivity or anaphylaxis upon administration of proinsulin peptidesPotential for disease acceleration or exacerbation of autoimmune beta-cell destruction if T cells are inadvertently activatedHLA restriction limits the addressable patient populationOff-target immune suppression or bystander immune activation
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

C-peptide levelsProinsulin-specific CD4+ T-cell frequencyInterferon-gamma (IFN-g) productionInterleukin-10 (IL-10) productionHLA-DR4 (HLA-DRB1*04:01) genotypeHLA-DQ8 genotypeHLA-DQ2 genotype

Beyond the preview

Go deeper on Proinsulin-specific CD4 T-cell receptor (Proinsulin-specific CD4 TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proinsulin-specific CD4 T-cell receptor (Proinsulin-specific CD4 TCR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call